Therefore, inhibition of Drp1 by mdivi-1 treatment or knockdown of Drp1 by siRNA enhanced cisplatin sensitivity of ovarian cancer cells under hypoxia [18]. This evidence concerns the gene DNM1L and ovarian cancer.